Covid-19: Moderna soars 18% as vaccine gives promising early results

The vaccine will move into a much larger late-stage trial later this month
Moderna’s Covid-19 vaccine produced antibodies to the coronavirus in all patients tested in an initial safety trial, federal researchers said, clearing an important milestone as the US continues to grapple with a surge in new infections.

The US biotech firm’s breakthrough is one of the most promising developments yet in the race to develop a vaccine against the virus that has paralysed the world’s economy. Yet the road to a successful shot is filled with hurdles, and some patients in the trial experienced severe side effects.

Moderna’s shares gained about 18 per cent in US on Wednesday, as stocks of other companies researching vaccines for the virus also rose. Moderna’s stock has almost quadrupled in value this year on hopes that the company’s vaccine will gain rapid approval. The vaccine will move into a much larger late-stage trial later this month that’s likely to determine whether it’s fit for commercial use.


“The good news is that this vaccine induced antibodies,” said Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases. “Not just any kind of antibodies, but neutralising antibodies.”

Fauci called the Moderna data “really quite promising”. Though he said the side effects seen were not alarming and were typical of those experienced with other vaccines, some experts sounded a note of caution.

More than half of participants who got the middle of three doses administered in the trial suffered mild to moderate fatigue, chills, headache, and muscle pain. Also, 40 per cent of people in the middle-dose group experienced a fever after the second vaccination. Three of 14 patients given the highest dose experienced severe side effects, but that dose is not being used in larger trials.



Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel